linjc16/ctgov huggingface dataset:
Building a Community-based Network to Promote Smoking Cessation

Study Overview
=================
Brief Summary
-----------------
This study describes the development of a community-based network to promote smoking cessation among female smokers in Hong Kong.

Detailed Description
-----------------
There is growing concern about the use of tobacco among women in Hong Kong. Nevertheless, nearly all of them reported that they had not attended smoking cessation services provided by the government and other organizations, of which only 6.7% indicated that they would like to attend, demonstrating the need for population-based smoking cessation interventions targeting female smokers in Hong Kong. In response to the increased number of female smokers and their low usage rates of smoking cessation services, the first smoking cessation hotline for female smokers in Hong Kong was established in 2006 by the University of Hong Kong. The aim of this study was to describe the development of a community-based network to promote the smoking cessation hotline among female smokers in Hong Kong.

Official Title
-----------------
Development of a Community-based Network to Promote Smoking Cessation Among Female Smokers in Hong Kong

Conditions
-----------------
Smoking

Intervention / Treatment
-----------------
* Behavioral: A brief intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Hong Kong Chinese current smokers Aged 15 years or above Able to speak and understand Cantonese Willing to receive face-to-face or telephone counseling Exclusion Criteria: Those who were participating in other smoking cessation programs or services
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Referred women<br>A brief intervention based on the'5 A' model developed by the Agency for Health Care Policy and Research in the United States. | Behavioral: A brief intervention<br>* The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| self-reported 7-day point prevalence of abstinence |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| self-reported reduction of ≥ 50% in cigarette consumption |  | 6 months | 
| Levels of self-efficacy at baseline |  | baseline | 
| Levels of self-efficacy at six months |  | six months |
Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)

Study Overview
=================
Brief Summary
-----------------
The aim of this prospective study is to evaluate the results of polidocanol sclerotherapy of pharynx for OSAS & SS,to reduce pharyngeal compliance.

Detailed Description
-----------------
Polidocanol submucous sclerosis in the part of pharynges with 1% polidocanol injection.The injection should be in the retropharyngeal submucosa and lateral pharyngeal bands and lateral pharyngeal submucosa and in front submucosa of soft palate.The injection is multi-point,and each point injection is 0.3 0.5ml;the total quantity/each time is not more than 5ml.Every patient have to be treated about 1 2 time.

Official Title
-----------------
Preliminary Study on Submucous Sclerosis of Pharynges With 1% Polidocanol to Treat Obstructive Sleep Apnea (OSA) & Snoring Subjects (SS)

Conditions
-----------------
Apnea, Snoring

Intervention / Treatment
-----------------
* Drug: Polidocanol Sclerotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: OSAS & SS which palatopharyngeal collapse. Exclusion Criteria: obstructive sleep apnea syndrome (osas) & snoring subjects (ss),which anatomic narrow result in.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Polidocanol Sclerotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| apnea-hypopnea index (AHI)is on polysomnography(PSG),to compare AHIanterior and posterior treatment. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial oxygen saturation (SaO2) and body mass index (BMI)will be measured on polysomnography |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep Apnea,Obstructive, apnea-hypopnea index (AHI), polidocanol, sclerotherapy, pharynges
Effect of Mass Deworming on Child Growth

Study Overview
=================
Brief Summary
-----------------
The purpose of the study was to determine whether periodical mass deworming improves growth in children below six years of age.

Detailed Description
-----------------
Many children in developing countries get slowed growth because of heavy loads of intestinal helminths. Quite often treatment is not sought because there may not be any obvious symptoms. Slowed growth may manifest as low weight for age or low height for age. The objective of the study was to estimate the effectiveness of the delivery of an anthelmintic drug through a community child health program on the weight gain of preschool aged children. Design: This was a cluster randomized controlled trial in 48 parishes in Eastern Uganda. All 48 parishes were participating in a new program for child health; 24 were randomly assigned to offer to children an additional service of anthelmintic treatment. The intervention was 400 mg of albendazole added to the standard services at child days over a 3 years period. All children were offered the drug and the main outcome measure was weight gain. Results: A total of 27,995 children were recruited into the 2 arms of the study with 14,940 in the treatment arm and 13,055 in the control arm. The intervention arm got an increase in weight gain of about 10% (166 grams per child per year (CI: 16-316) above expected weight gain when treatment was taken twice a year and an increase of 5% when treatment was received approximately annually. Conclusion: The inclusion of deworming in regularly scheduled health services appears practical and capable of increasing child growth.

Official Title
-----------------
Increased Weight Gain in Preschool Children Due to Mass Albendazole Treatment Given During Child Health Days in Uganda

Conditions
-----------------
Low Weight for Age in Preschool Children

Intervention / Treatment
-----------------
* Drug: Albendazole 400 mg, given 6 monthly


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children 1-6 years Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Albendazole 400 mg, given 6 monthly|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight gain |  |  | 
| weight for age |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
underweight, preschool, mass deworming
Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)

Study Overview
=================
Brief Summary
-----------------
Oral administration of Alequel, a mixture of proteins derived from the patient's bowel will be tested in patients with inflammatory bowel disease.

Detailed Description
-----------------
Oral administration of Alequel prepared from patients biopsies will be tested in patients with inflammatory bowel disease to determine its anti inflammatory effect.

Official Title
-----------------
Phase 2 Clinical Trial for Oral Administration of Alequel for Patients With IBD

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Drug: Alequel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Crohn's disease Exclusion Criteria: Immune suppression

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AlequelTM<br>AlequelTM | Drug: Alequel<br>* Alequel<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Improved in Disease Activity |  | 15 weeks |
Comparative Study of Two Multifocal Intraocular Lens With Different Add Power

Study Overview
=================
Brief Summary
-----------------
This study will compare cataract patients with implantation of diffractive multifocal IOL with an additional power of +2.75 diopters (Group 1) and with +3.25 diopters (Group 2). Evaluations will be performed 1 and 3 months following cataract surgery, including measurement of uncorrected distance visual acuity (UDVA), refractive error (manifest refraction [MR]), and uncorrected near visual acuity (UNVA) at 33, 40, and 50 cm. At 3 months, internal aberrations and contrast sensitivity will be evaluated and subjects will complete a questionnaire on outcomes satisfaction, visual symptoms, and spectacle use.

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Device: +2.75 diopters multifocal intraocular lens
* Device: +3.25 diopters multifocal intraocular lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >= 18 cataract patients with lens opacities classification higher than grade III patients who desire to be spectacle indepence for distance and near vision Exclusion Criteria: previous ocular surgery or trauma presence of corneal opacities fundus abnormalities glaucoma uveitis amblyopia systemic disease posterior capsule rupture during cataract surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 2.75 group<br>Patients with 2.75 diopters multifocal intraocular lens | Device: +2.75 diopters multifocal intraocular lens<br> <br> |
| Active Comparator: 3.25 group<br>Patients with +3.25 diopters multifocal intraocular lens | Device: +3.25 diopters multifocal intraocular lens<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity | Uncorrected distance visual acuity and uncorrected near visual acuity | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contrast sensitivity measured by the Functional Acuity Contrast Test (FACT) of the Optec 6500 view-in test system | Internal aberrations measured by the ray-tracing aberrometer and contrast sensitivity measured by the Functional Acuity Contrast Test (FACT) of the Optec 6500 view-in test system | 3 months | 
| internal aberration measured by the ray-tracing aberrometer | Internal aberrations measured by the ray-tracing aberrometer and contrast sensitivity measured by the Functional Acuity Contrast Test (FACT) of the Optec 6500 view-in test system | 3 months |
Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to assess the comparative gastrointestinal (GI) tolerance of normal term infants to two experimental soy-based formulas, relative to a commercially available soy-based formula.

Official Title
-----------------
Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants

Conditions
-----------------
Infant, Newborn

Intervention / Treatment
-----------------
* Other: soy protein formula
* Other: Commercially available soy formula
* Other: Soy formula experimental #2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infant is judged to be in good health. Infant is a singleton from a full term birth with a gestational age of 37-42 weeks. Infant's birth weight was > 2490 g ( 5 lb 8 oz). Infant is between 0 and 8 days of age at enrollment. Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study. Parent(s) confirm their intention not to administer vitamin or mineral supplements, solid foods or juices to their infant for the duration of the study. Infants using medications or home remedies, herbal preparations or rehydration/intravenous (IV) fluids that might affect GI tolerance may not be enrolled. Exclusion Criteria: An adverse maternal, fetal or infant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development. Infant has been treated with antibiotics. Infant has received probiotics.

Ages Eligible for Study
-----------------
Maximum Age: 8 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1: Soy formula<br>experimental soy formula #1 | Other: soy protein formula<br>* ad lib for 0-35 days of age<br>* Other names: experimental soy formula;|
| Active Comparator: 2: Soy Formula<br>Commercially available soy formula | Other: Commercially available soy formula<br>* ad lib for 0-35 days of age<br>|
| Experimental: 3: Soy formula<br>experimental soy formula #2 | Other: Soy formula experimental #2<br>* ad lib for 0-35 days of age<br>* Other names: Experimental soy formula;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gastrointestinal tolerance from Study Visit 1 to Study Visit 3 at 35 days of age. |  | 35 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Additional gastrointestinal measures of tolerance from Study Visit 1 to Study Visit 3 at 35 days of age |  | 35 days |
Safety and Feasibility of Reversible Induction Strategy

Study Overview
=================
Brief Summary
-----------------
This study would explore the safety and feasibility of a reversible induction strategy for uncertain difficult airway. This reversible induction strategy would include high flow nasal canular oxygenation support, short-term effect anesthetic including Propofol and Remifentanil for sedation and analgesia and Sugammadex would be used for reverse the muscle relaxant.

Official Title
-----------------
Safety and Feasibility of Reversible Induction Strategy Supported by HFNC Combined With Specific Anesthetic

Conditions
-----------------
Patients With Uncertain Difficult Airway, Colon Cancer, Gastric Cancer, Prostatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years old,<65 years old Signed informed consent Undergoing selective operation （ time of operation is over two hours） ASA classification I-II Mallampati classification 3-4 suspicious difficult airway, but the anesthetists decide to try to rapid induction Exclusion Criteria: Patients with several dysfunctions of liver, kidney or heart) Patients with a full stomach or have other risk factors of reflux aspiration Any medicine was taken before surgery, which might enhance or mitigate the effects of muscle relaxant Infection of the mouth or nose Allergy history of any medicine which would be used in this study Pregnant and lactating women Patients with neuromuscular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful rate of reversion |  | From the beginning of induction to 15min later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TOFr 0.9 reversion time |  | From the beginning of induction to 15min later | 
| BIS 80 reversion time |  | From the beginning of induction to 15min later | 
| Tidal volume 6-8ml tidal volume 6-8ml/kg reversion time |  | From the beginning of induction to 15min later | 
| consciousness reversion time |  | From the beginning of induction to 15min later | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
THRIVE, Uncertain difficult airway, Reversible induction strategy
Fertility After Intrauterine Tamponing Balloon: Where Are we

Study Overview
=================
Brief Summary
-----------------
Today, few data are available on the patient's fertility following intrauterine tamponade balloon (BTIU) used for postpartum hemorrhage (PPH) after vaginal delivery (AVB). Several studies have concluded that there are no fertility disorders after conservative surgical treatment or embolization. BTIU is an essential treatment in the management of PPH. The aim was to evaluate post-BTIU fertility and the appearance of gynecological symptoms. This is a bicentric retrospective study (Valenciennes, Lille, France), between 2012 and 2017. The data will be collected by telephone interview on fertility and various gynecological functional symptoms.

Official Title
-----------------
Evaluation of Fertility of Patients With a History of Postpartum Hemorrhage, Complicating Low-dose Delivery With Intrauterine Tamponade Treatment

Conditions
-----------------
Hemorrhage Postpartum, Fertility Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Vaginal birth Post partum haemorrhage Intrauterine tamponing balloon Between 2012 and 2017 CHRU Lille and CH Valenciennes Exclusion Criteria: Minor patients Initial intake started in another center (postpartum transfer). Refusal to participate in the study Invasive treatments for postpartum haemorrhage Caesarean

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of infertility | defined as the absence of pregnancy after 12 months of attempted pregnancy. | 7 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to obtain a new pregnancy evaluating the stop of contraceptionand desire for pregnancy |  | 7 years | 
| Frequency of gynecological complications after use of an intrauterine tamponade balloon. |  | 7 years | 
| Type of gynecological complications after use of an intrauterine tamponade balloon. | type = infections , pelvic pain, cycle disorders | 7 years | 
| the frequency of obstetric complications for the next pregnancy |  | 7 years | 
| type of obstetrical complications | complications = intrauterine growth retardation, threat of premature labor | 7 years | 
| Frequency of recurrent postpartum haemorrhage in the next pregnancy |  | 7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemorrhage Post-partum, Fertility, Uterine balloon tamponade, Vaginal Birth